Methotrexate, homocysteine, and seizures.
Quinn
C T
CT
Griener
J C
JC
Bottiglieri
T
T
Kamen
B A
BA
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000134:cerebrospinal fluid; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003545:Cysteine / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid; D004830:Epilepsy, Tonic-Clonic / Q000134:cerebrospinal fluid*; D006710:Homocysteine / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid; D006801:Humans; D007223:Infant; D008297:Male; D008727:Methotrexate / Q000009:adverse effects* / Q000134:cerebrospinal fluid; D018377:Neurotransmitter Agents; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000134:cerebrospinal fluid* / Q000188:drug therapy
D000964:Antimetabolites, Antineoplastic; D018377:Neurotransmitter Agents; D006710:Homocysteine; C007956:homocysteic acid; D003545:Cysteine; C013461:cysteine sulfinic acid; D008727:Methotrexate